News
MDNAF
0.300
-0.92%
-0.003
Weekly Report: what happened at MDNAF last week (0831-0904)?
Weekly Report · 4d ago
Medicenna to Spotlight Superkine Pipeline at H.C. Wainwright Global Investment Conference
TipRanks · 09/03 11:41
Weekly Report: what happened at MDNAF last week (0824-0828)?
Weekly Report · 08/31 09:58
Weekly Report: what happened at MDNAF last week (0817-0821)?
Weekly Report · 08/24 09:59
Weekly Report: what happened at MDNAF last week (0810-0814)?
Weekly Report · 08/17 10:00
Medicenna Therapeutics Corp. GAAP EPS of -$0.06
Seeking Alpha · 08/14 14:18
Medicenna Advances Superkine Pipeline With New Data and Regulatory Plans
TipRanks · 08/14 11:33
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
Barchart · 08/14 06:00
Weekly Report: what happened at MDNAF last week (0803-0807)?
Weekly Report · 08/10 09:56
Weekly Report: what happened at MDNAF last week (0727-0731)?
Weekly Report · 08/03 09:55
Weekly Report: what happened at MDNAF last week (0720-0724)?
Weekly Report · 07/27 09:59
Weekly Report: what happened at MDNAF last week (0713-0717)?
Weekly Report · 07/20 09:56
Weekly Report: what happened at MDNAF last week (0706-0710)?
Weekly Report · 07/13 09:57
Weekly Report: what happened at MDNAF last week (0629-0703)?
Weekly Report · 07/06 10:00
Weekly Report: what happened at MDNAF last week (0622-0626)?
Weekly Report · 06/29 09:57
Medicenna Therapeutics Corp. GAAP EPS of -C$0.22
Seeking Alpha · 06/26 12:51
Weekly Report: what happened at MDNAF last week (0615-0619)?
Weekly Report · 06/22 10:03
Weekly Report: what happened at MDNAF last week (0608-0612)?
Weekly Report · 06/15 10:04
Weekly Report: what happened at MDNAF last week (0601-0605)?
Weekly Report · 06/08 10:01
Weekly Report: what happened at MDNAF last week (0525-0529)?
Weekly Report · 06/01 10:04
More
Webull provides a variety of real-time MDNAF stock news. You can receive the latest news about Medicenna Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About MDNAF
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.